Longitudinalase ® is applied subcutaneously (near the lesion site or under the scar tissue) or intramuscularly at a dose of 3000 ME a course of 5 to 25 injections (depending on the disease) with an interval between administrations from 3 to 10 days.
Methods of application are chosen by the doctor depending on the diagnosis, severity of the disease, clinical course, age of the patient. If necessary, a second course is recommended after 2-3 months.
In the case of treatment of diseases accompanied by a severe chronic productive process in connective tissue, after a standard course, prolonged maintenance therapy with Longidase 3000 ME with interruptions between injections - 10-14 days.
To increase the bioavailability of drugs and diagnostic agents, a dose of 1500 ME at preliminary for 10-15 minutes intramuscular or hypodermic introduction in the same place, as the basic preparation.
Breeding:
- Contents of the ampoule or bottle of Longidasa® 3000 ME are dissolved in 1.0-2.0 ml of the procaine solution (0.25% or 0.5%).In case of procaine intolerance, Longidasa® is dissolved in the same volume of a 0.9% sodium chloride solution for injection or water for injection.
- When used to increase bioavailability, the contents of the ampoule or vial of Longidase® 3000 ME is dissolved in 2.0 ml, and with a dosage of 1500 ME in 1.0 ml of sodium chloride solution 0.9% for injection.
The solvent in the vial or ampoule should be injected slowly, soak for 2-3 minutes, gently stir, not shaking, so as not to foam the protein. The prepared solution for parenteral administration is not subject to storage.
Do not administer intravenously!
Recommended schemes of prevention and treatment
For prevention adhesions and gross scarring after surgery on the organs of the abdominal cavity and small pelvis intramuscularly at a dosage of 3000 ME 1 every 3 days with 5 injections. If necessary, the use of the Longidasa® preparation can be continued by a general course of up to 10 injections when administered once every 5 days,
For treatment:
in gynecology:
- adhesive process in the small pelvis with inflammatory diseases of internal genitalia intramuscularly by 3000 ME 1 every 3-5 days with a course of 10-15 injections;
- tubal peritoneal infertility intramuscularly to 3000 ME a common course for up to 15 injections: the first 5 injections 1 every 3 days, then 1 every 5 days;
in urology:
- chronic prostatitis intramuscularly to 3000 ME 1 every 5 days, course of 10-15 injections;
- interstitial cystitis intramuscularly to 3000 ME 1 every 5 days, up to 10 injections;
in surgery:
- an adhesion disease after surgical interventions on the organs of the abdominal cavity intramuscularly at a dosage of 3000 ME 1 every 3-5 days with a course of 10 to 15 injections;
- long-term non-healing wounds intramuscularly at a dosage of 3000 ME 1 every 5 days with a course of 5-10 injections;
in dermatovenereology, cosmetology:
- intramuscularly scleroderma by 3000-4500 ME 1 time in 3-5 days with a course of up to 20 injections. Dosage and course are selected individually depending on the clinical course, stage, localization of the disease and individual characteristics of the patient;
- keloid, hypertrophic and emerging scars after pyoderma, burns, surgeries, trauma: intradermal or subcutaneous injection near the site of the lesion once every 3 days, with a course of up to 15 injections at a dosage of 3000-4500 ME. The amount of dilution of the Longidas preparation * is chosen by the doctor depending on the number of injection points. If necessary, the course can be continued on a schedule once every 5 days to 25 injections.Depending on the area of skin lesion, the prescription of scar formation, it is possible to alternate subcutaneous and intramuscular administration once every 5 days in a dosage of 3000 ME, course up to 20 injections.
in pulmonology and phthisiology:
- pneumosclerosis intramuscularly to 3000 ME 1 every 5 days with a course of 10 injections;
- fibrosing alveolitis intramuscularly at a dosage of 3000 ME 1 every 5 days with a course of 15 injections, then maintenance therapy once every 10 days with a general course up to 25 injections;
- intramuscular injection at dosage of 3000 ME 1 every 5 days with a course of up to 25 injections; depending on the clinical picture and the severity of the course of the disease, long-term therapy is possible (from 6 months to 1 year at a dosage of 3000 ME 1 time in 10 days);
in orthopedics:
- contracture of the joints subcutaneously near the lesion in a dosage of 3000 ME 1 every 3 days with a course of 5 to 15 injections;
- arthrosis, ankylosing spondylitis, subcutaneously near the lesion in a dosage of 3000 ME 1 every 3 days with a course of up to 15 injections, if necessary, treatment can be continued with injections once every 5 days. The duration of maintenance therapy is chosen by the doctor depending on the severity of the disease;
- hematomas subcutaneously near the lesion in a dosage of 3000 ME 1 every 3 days for up to 5 injections;
to increase bioavailability: when combined subcutaneously or intramuscularly with diagnostic or medicinal products (antibiotics, chemotherapy, anesthetics, etc.). Longitudinalase® is administered preliminary for 10-15 minutes at a dosage of 1500 ME in the same way and in the same place as the main drug.